Chronic pain is a serious health problem that affects millions globally by decreasing their
quality of life, social activities, and hours of restful sleep. It usually presents psychological …

Effective and safe treatment of patients with neuropathic pain (NP), despite the emergence
of new clinical trials, remains a challenge for clinicians. A review of epidemiological data …

Neuropathic pain (NP), in view of its non-nociceptive component, is not caused by
physiological lesions but by problems in the nervous system itself, whether in the central …

Disclaimer statement: Managing neuropathic pain is a very complex topic and should
encompass using different approaches including pharmacological and non …

Pregabalin is an α2-δ ligand indicated for the treatment of peripheral and central
neuropathic pain. In this article, we will review the pharmacodynamics, pharmacokinetics …

Abstract Gabapentin (Neurontin) and pregabalin (Lyrica) are first-and second-generation
α2δ ligands, respectively, and are both approved for use as adjunctive therapy in pain …

Aims: Conventional approaches to the management of neuropathic pain (NeP) often yield
unsatisfactory results. We aimed to investigate pregabalin, a gamma‐aminobutyric acid …

Pregabalin is an antagonist of voltage gated Ca2+ channels and specifically binds to alpha-
2-delta subunit to produce antiepileptic and analgesic actions. It successfully alleviates the …

Chronic 'pathological'pain is sustained by mechanisms of peripheral and central
sensitization, which are being increasingly investigated at the molecular and cellular levels …

Central neuropathic pain (central pain) is treated with antidepressants, various
anticonvulsants, opioids, and cannabinoids, but in many cases treatment is insufficient and …